Creative Visionary Nicola Formichetti Named Global Creative Director, M·A·C Cosmetics
14.5.2025 16:10:00 CEST | Business Wire | Press Release
The Estée Lauder Companies (NYSE:EL) and M·A·C Cosmetics announced today the appointment of Nicola Formichetti as Global Creative Director, effective May 19, 2025. A celebrated creative director, designer, and cultural icon, Formichetti brings his visionary artistry, genre-defying creativity and consumer-first mindset to the helm of M·A·C’s global creative strategy. He will report directly to Aïda Moudachirou-Rébois, M·A·C’s Senior Vice President and Global General Manager.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250514389264/en/
Photograph by Matthew Brookes
Formichetti’s appointment marks a pivotal moment for M·A·C as the brand continues to shape the future of beauty through boundary-pushing innovation and cultural relevance. His dynamic approach to creativity, rooted at the intersection of fashion, music, culture, and technology, will spark new levels of desirability for M·A·C, driving its product innovation, creative collaborations, and global consumer engagement. In his new role, Formichetti will shape the strategy, conceptualization and execution of M·A·C’s creative vision, elevating the brand’s global image and impact across every touchpoint – from campaigns and social media platforms to product, packaging, and immersive retail experiences. At its core, M·A·C is built on artistry – and as an artist and visionary himself, Formichetti will play a central role in reimagining what artistry means for the next generation of consumers. He will lead a multidisciplinary creative team, building on the brand’s iconic heritage in artistry, trendsetting, limitless self-expression and individuality to deliver bold storytelling that leaves a lasting impression on a global scale.
“Nicola is a once-in-a-generation creative talent who perfectly embodies the bold, fearless energy of M·A·C and our global community,” said Aïda Moudachirou-Rébois. “Like our consumers, Nicola is passionate, expressive and knows how to push boundaries. His appointment is not only a celebration of artistry, but a reflection of our commitment to serving our consumers with of-the-moment relevance, creativity and authenticity. He is the perfect Creative Director to drive the brand into its next exciting chapter.”
Renowned for his genre-defying work with global superstars like Lady Gaga, his creative oversight of some of fashion’s most influential houses, and his reputation for trend-defining collaborations, Formichetti is uniquely equipped to help M·A·C deliver on its mission to be a brand for “All Ages, All Races, All Genders.” Drawing from his Japanese and Italian heritage, he brings a globally attuned perspective that resonates deeply with M·A·C’s inclusive ethos. His forward-thinking approach seamlessly integrates technology and digital innovation, pushing creative boundaries and redefining how beauty and fashion engage with global audiences.
“Nicola’s appointment is a bold step forward for M·A·C and for The Estée Lauder Companies,” said Jane Hertzmark Hudis, Executive Vice President, Chief Brand Officer, The Estée Lauder Companies. “Nicola brings the vision, bold creativity and track record to take the M·A·C brand to new heights as it enters its next phase of growth. We are thrilled to bring this level of high-caliber creative talent to The Estée Lauder Companies.”
“This appointment represents yet another definitive step forward for The Estée Lauder Companies as we execute our recently announced Beauty Reimagined vision, which is focused on becoming the most consumer-centric prestige beauty company in the world,” said Stéphane de La Faverie, President and CEO, The Estée Lauder Companies. “A key component of Beauty Reimagined is meeting consumers where they are, and with Nicola’s unique ability to capture the pulse of culture, he will help shape exciting and innovative products and experiences. M·A·C’s tremendous brand equity is most powerful when it evolves with the times—and Nicola will leverage his creative vision to inspire a new generation of connection, self-expression, and loyalty.”
“M·A·C is an iconic brand that has always championed the people and communities that move culture forward,” said Formichetti. “Having previously collaborated with the brand on my Nicopanda collection and the M·A·C VIVA GLAM campaign, I’m thrilled to return and bring my vision to this next chapter. The world is craving creativity, beauty, and connection—and I can’t wait to help bring that to life in a magical way.”
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include those in the various quotations. Although the Company believes that its expectations are based on reasonable assumptions within the bounds of its knowledge of its business and operations, actual results may differ materially from the Company’s expectations. Factors that could cause actual results to differ from expectations include the ability to successfully implement its strategy, including the Company’s profit recovery and growth plan; successfully transition its leadership; and those other factors described in the Company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K. The Company assumes no responsibility to update forward-looking statements made herein or otherwise.
About The Estée Lauder Companies
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers, marketers, and sellers of quality skin care, makeup, fragrance, and hair care products, and is a steward of luxury and prestige brands globally. The Company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, M·A·C, La Mer, Bobbi Brown Cosmetics, Aveda, Jo Malone London, Bumble and bumble, Darphin Paris, TOM FORD, Smashbox, AERIN Beauty, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, Too Faced, Dr.Jart+, the DECIEM family of brands, including The Ordinary and NIOD, and BALMAIN Beauty.
ELC-L
ELC-B
View source version on businesswire.com: https://www.businesswire.com/news/home/20250514389264/en/
Contacts
Media Relations:
Diederik Koenders
dkoenders@maccosmetics.com
Investor Relations:
Rainey Mancini
rmancini@estee.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press Release
Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom